Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,21898816,flow rate,"Separation was achieved on a CN column (200 mm×4.6 mm) using acetonitrile-10 mM orthophosphoric acid containing 1 mL/L triethylamine (45:55, v/v) at a flow rate of 1 mL/min.",A new HPLC method with fluorescence detection for the determination of memantine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21898816/),[ml] / [min],1,6200,DB00915,Amantadine
,21898816,Limit of detection,"Limit of detection and limit of quantification were found to be 0.3 and 1.0 ng/mL, respectively.",A new HPLC method with fluorescence detection for the determination of memantine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21898816/),[ng] / [ml],0.3,6201,DB00915,Amantadine
,21898816,limit of quantification,"Limit of detection and limit of quantification were found to be 0.3 and 1.0 ng/mL, respectively.",A new HPLC method with fluorescence detection for the determination of memantine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21898816/),[ng] / [ml],1.0,6202,DB00915,Amantadine
,21898816,recovery,Average recovery was also found to be around 94%.,A new HPLC method with fluorescence detection for the determination of memantine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21898816/),%,94,6203,DB00915,Amantadine
,7756105,apparent volume of distribution (V2/F),"Its apparent volume of distribution (V2/F) was higher in smokers than nonsmokers, 6.05 +/- 0.86 vs 4.87 +/- 0.85 l kg-1; (mean +/- s.d., 10/group, P < 0.011), and no gender-associated effect was observed.",Chronic tobacco smoking and gender as variables affecting amantadine disposition in healthy subjects. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756105/),[l] / [kg],6.05,15445,DB00915,Amantadine
,7756105,apparent volume of distribution (V2/F),"Its apparent volume of distribution (V2/F) was higher in smokers than nonsmokers, 6.05 +/- 0.86 vs 4.87 +/- 0.85 l kg-1; (mean +/- s.d., 10/group, P < 0.011), and no gender-associated effect was observed.",Chronic tobacco smoking and gender as variables affecting amantadine disposition in healthy subjects. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756105/),[l] / [kg],4.87,15446,DB00915,Amantadine
,7756105,urinary recovery,"Renal clearance did not vary with time-interval, but urinary recovery at 48 h was higher in men than in women (60.2 +/- 7.5% vs 47.0 +/- 15.0%, P < 0.032).",Chronic tobacco smoking and gender as variables affecting amantadine disposition in healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756105/),%,60.2,15447,DB00915,Amantadine
,7756105,urinary recovery,"Renal clearance did not vary with time-interval, but urinary recovery at 48 h was higher in men than in women (60.2 +/- 7.5% vs 47.0 +/- 15.0%, P < 0.032).",Chronic tobacco smoking and gender as variables affecting amantadine disposition in healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756105/),%,47.0,15448,DB00915,Amantadine
,7756105,renal clearances,"Males had higher renal clearances than females when normalised for body mass index (BMI, 0.492 +/- 0.284 vs 0.248 +/- 0.137 l-1 BMI h-1, (10/group, P < 0.032)).",Chronic tobacco smoking and gender as variables affecting amantadine disposition in healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756105/),1/[l],0.492,15449,DB00915,Amantadine
,7756105,renal clearances,"Males had higher renal clearances than females when normalised for body mass index (BMI, 0.492 +/- 0.284 vs 0.248 +/- 0.137 l-1 BMI h-1, (10/group, P < 0.032)).",Chronic tobacco smoking and gender as variables affecting amantadine disposition in healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756105/),1/[l],0.248,15450,DB00915,Amantadine
,7756105,weight normalised renal clearance,"On combining data from a previous study, the weight normalised renal clearance was also higher in men than in women, 0.160 +/- 0.075 vs 0.102 +/- 0.053 l kg-1 h-1 (19/group, P < 0.01).",Chronic tobacco smoking and gender as variables affecting amantadine disposition in healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756105/),[l] / [h·kg],0.160,15451,DB00915,Amantadine
,7756105,weight normalised renal clearance,"On combining data from a previous study, the weight normalised renal clearance was also higher in men than in women, 0.160 +/- 0.075 vs 0.102 +/- 0.053 l kg-1 h-1 (19/group, P < 0.01).",Chronic tobacco smoking and gender as variables affecting amantadine disposition in healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756105/),[l] / [h·kg],0.102,15452,DB00915,Amantadine
,25427541,CMAX,The mean (range) amantadine CMAX was 275 ng/mL (225-351 ng/mL) at 2.6 h (1-4 h) with a terminal half-life of 4.96 h (4.11-6.59 h).,Pharmacokinetics of oral amantadine in greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25427541/),[ng] / [ml],275,18247,DB00915,Amantadine
,25427541,terminal half-life,The mean (range) amantadine CMAX was 275 ng/mL (225-351 ng/mL) at 2.6 h (1-4 h) with a terminal half-life of 4.96 h (4.11-6.59 h).,Pharmacokinetics of oral amantadine in greyhound dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25427541/),h,4.96,18248,DB00915,Amantadine
,20129511,total body clearance,Amantadine total body clearance was 0.17 L/h/kg with a half-life of 13.9 hours.,Pharmacokinetics of amantadine in children with impaired consciousness due to acquired brain injury: preliminary findings using a sparse-sampling technique. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20129511/),[l] / [h·kg],0.17,18414,DB00915,Amantadine
,20129511,half-life,Amantadine total body clearance was 0.17 L/h/kg with a half-life of 13.9 hours.,Pharmacokinetics of amantadine in children with impaired consciousness due to acquired brain injury: preliminary findings using a sparse-sampling technique. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20129511/),h,13.9,18415,DB00915,Amantadine
,7840556,elimination half-life,"GG167 was metabolically stable, with an elimination half-life of 10 min following intravenous administration.","Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7840556/),min,10,25260,DB00915,Amantadine
,32700994,maximum plasma concentration,"Mean ± SD maximum plasma concentration, time to maximum plasma concentration, half-life, and area under the concentration-versus-time curve from the last dose to infinity were 1,174 ± 186 ng/mL, 3.8 ± 1.8 hours, 23.2 ± 2.9 hours, and 38.6 ± 7.4 μg·h/mL, respectively, after a single dose and 1,185 ± 270 ng/mL, 3.0 ± 2.4 hours, 21.5 ± 5.3 hours, and 26.3 ± 5.7 μg·h/mL, respectively, at steady state after multiple doses.",Pharmacokinetics of amantadine after oral administration of single and multiple doses to orange-winged Amazon parrots (Amazona amazonica). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32700994/),[ng] / [ml],"1,174",28524,DB00915,Amantadine
,32700994,half-life,"Mean ± SD maximum plasma concentration, time to maximum plasma concentration, half-life, and area under the concentration-versus-time curve from the last dose to infinity were 1,174 ± 186 ng/mL, 3.8 ± 1.8 hours, 23.2 ± 2.9 hours, and 38.6 ± 7.4 μg·h/mL, respectively, after a single dose and 1,185 ± 270 ng/mL, 3.0 ± 2.4 hours, 21.5 ± 5.3 hours, and 26.3 ± 5.7 μg·h/mL, respectively, at steady state after multiple doses.",Pharmacokinetics of amantadine after oral administration of single and multiple doses to orange-winged Amazon parrots (Amazona amazonica). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32700994/),h,3.8,28525,DB00915,Amantadine
,32700994,half-life,"Mean ± SD maximum plasma concentration, time to maximum plasma concentration, half-life, and area under the concentration-versus-time curve from the last dose to infinity were 1,174 ± 186 ng/mL, 3.8 ± 1.8 hours, 23.2 ± 2.9 hours, and 38.6 ± 7.4 μg·h/mL, respectively, after a single dose and 1,185 ± 270 ng/mL, 3.0 ± 2.4 hours, 21.5 ± 5.3 hours, and 26.3 ± 5.7 μg·h/mL, respectively, at steady state after multiple doses.",Pharmacokinetics of amantadine after oral administration of single and multiple doses to orange-winged Amazon parrots (Amazona amazonica). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32700994/),h,23.2,28526,DB00915,Amantadine
,32700994,area under the concentration-versus-time curve from the last dose to infinity,"Mean ± SD maximum plasma concentration, time to maximum plasma concentration, half-life, and area under the concentration-versus-time curve from the last dose to infinity were 1,174 ± 186 ng/mL, 3.8 ± 1.8 hours, 23.2 ± 2.9 hours, and 38.6 ± 7.4 μg·h/mL, respectively, after a single dose and 1,185 ± 270 ng/mL, 3.0 ± 2.4 hours, 21.5 ± 5.3 hours, and 26.3 ± 5.7 μg·h/mL, respectively, at steady state after multiple doses.",Pharmacokinetics of amantadine after oral administration of single and multiple doses to orange-winged Amazon parrots (Amazona amazonica). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32700994/),[h·μg] / [ml],38.6,28527,DB00915,Amantadine
,32700994,area under the concentration-versus-time curve from the last dose to infinity,"Mean ± SD maximum plasma concentration, time to maximum plasma concentration, half-life, and area under the concentration-versus-time curve from the last dose to infinity were 1,174 ± 186 ng/mL, 3.8 ± 1.8 hours, 23.2 ± 2.9 hours, and 38.6 ± 7.4 μg·h/mL, respectively, after a single dose and 1,185 ± 270 ng/mL, 3.0 ± 2.4 hours, 21.5 ± 5.3 hours, and 26.3 ± 5.7 μg·h/mL, respectively, at steady state after multiple doses.",Pharmacokinetics of amantadine after oral administration of single and multiple doses to orange-winged Amazon parrots (Amazona amazonica). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32700994/),h,3.0,28528,DB00915,Amantadine
,32700994,area under the concentration-versus-time curve from the last dose to infinity,"Mean ± SD maximum plasma concentration, time to maximum plasma concentration, half-life, and area under the concentration-versus-time curve from the last dose to infinity were 1,174 ± 186 ng/mL, 3.8 ± 1.8 hours, 23.2 ± 2.9 hours, and 38.6 ± 7.4 μg·h/mL, respectively, after a single dose and 1,185 ± 270 ng/mL, 3.0 ± 2.4 hours, 21.5 ± 5.3 hours, and 26.3 ± 5.7 μg·h/mL, respectively, at steady state after multiple doses.",Pharmacokinetics of amantadine after oral administration of single and multiple doses to orange-winged Amazon parrots (Amazona amazonica). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32700994/),h,21.5,28529,DB00915,Amantadine
,32700994,area under the concentration-versus-time curve from the last dose to infinity,"Mean ± SD maximum plasma concentration, time to maximum plasma concentration, half-life, and area under the concentration-versus-time curve from the last dose to infinity were 1,174 ± 186 ng/mL, 3.8 ± 1.8 hours, 23.2 ± 2.9 hours, and 38.6 ± 7.4 μg·h/mL, respectively, after a single dose and 1,185 ± 270 ng/mL, 3.0 ± 2.4 hours, 21.5 ± 5.3 hours, and 26.3 ± 5.7 μg·h/mL, respectively, at steady state after multiple doses.",Pharmacokinetics of amantadine after oral administration of single and multiple doses to orange-winged Amazon parrots (Amazona amazonica). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32700994/),[h·μg] / [ml],26.3,28530,DB00915,Amantadine
,8330461,Renal clearance,Renal clearance of amantadine (13.2 +/- 5.8 L/hr) was significantly inhibited by quinine (9.7 +/- 4.8 L/hr) and quinidine (8.9 +/- 4.0 L/hr) only in male subjects and was not associated with age.,Gender and age as factors in the inhibition of renal clearance of amantadine by quinine and quinidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8330461/),[l] / [h],13.2,35751,DB00915,Amantadine
,8330461,Renal clearance,Renal clearance of amantadine (13.2 +/- 5.8 L/hr) was significantly inhibited by quinine (9.7 +/- 4.8 L/hr) and quinidine (8.9 +/- 4.0 L/hr) only in male subjects and was not associated with age.,Gender and age as factors in the inhibition of renal clearance of amantadine by quinine and quinidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8330461/),[l] / [h],9.7,35752,DB00915,Amantadine
,8330461,Renal clearance,Renal clearance of amantadine (13.2 +/- 5.8 L/hr) was significantly inhibited by quinine (9.7 +/- 4.8 L/hr) and quinidine (8.9 +/- 4.0 L/hr) only in male subjects and was not associated with age.,Gender and age as factors in the inhibition of renal clearance of amantadine by quinine and quinidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8330461/),[l] / [h],8.9,35753,DB00915,Amantadine
,17553649,limits of detection,"The limits of detection and quantification were 20 and 50 ng/ml for the analytes, respectively.",New method for high-performance liquid chromatographic determination of amantadine and its analogues in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17553649/),[ng] / [ml],20,36901,DB00915,Amantadine
,17553649,limits of detection,"The limits of detection and quantification were 20 and 50 ng/ml for the analytes, respectively.",New method for high-performance liquid chromatographic determination of amantadine and its analogues in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17553649/),[ng] / [ml],50,36902,DB00915,Amantadine
,23371894,clearance,The average clearance was 5.2 L/h with a 27 % inter-individual variability (percentage coefficient of variation).,Population pharmacokinetic study of memantine: effects of clinical and genetic factors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23371894/),[l] / [h],5.2,38303,DB00915,Amantadine
,30845734,IC50,"Among them, compounds 9f and 9j exhibited the promising anti-H3N2 activities with IC50 values of 7.2 μM and 10.2 μM, respectively, better than that of lead 1.",Evolution and Biological Evaluation of Matrinic Derivatives with Amantadine Fragments As New Anti-Influenza Virus Agents. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30845734/),μM,7.2,39768,DB00915,Amantadine
,30845734,IC50,"Among them, compounds 9f and 9j exhibited the promising anti-H3N2 activities with IC50 values of 7.2 μM and 10.2 μM, respectively, better than that of lead 1.",Evolution and Biological Evaluation of Matrinic Derivatives with Amantadine Fragments As New Anti-Influenza Virus Agents. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30845734/),μM,10.2,39769,DB00915,Amantadine
,28766500,C<sub>max</sub>,"The evaluated pharmacokinetic parameters (test vs. reference) including C<sub>max</sub> (18 ± 3.2 vs. 17.8 ± 3.4), AUC<sub>0-t</sub> (1,188.5 ± 222.2 vs. 1,170.9 ± 135.7), and AUC<sub>0-∞</sub> (1,353.3 ± 258.6 vs. 1,291.3 ± 136.7) values were assessed for bioequivalence based on current guidelines.",A bioequivalence study of two memantine formulations in healthy Chinese male volunteers . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28766500/),,18,60388,DB00915,Amantadine
,28766500,C<sub>max</sub>,"The evaluated pharmacokinetic parameters (test vs. reference) including C<sub>max</sub> (18 ± 3.2 vs. 17.8 ± 3.4), AUC<sub>0-t</sub> (1,188.5 ± 222.2 vs. 1,170.9 ± 135.7), and AUC<sub>0-∞</sub> (1,353.3 ± 258.6 vs. 1,291.3 ± 136.7) values were assessed for bioequivalence based on current guidelines.",A bioequivalence study of two memantine formulations in healthy Chinese male volunteers . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28766500/),,17.8,60389,DB00915,Amantadine
,28766500,AUC<sub>0-t</sub>,"The evaluated pharmacokinetic parameters (test vs. reference) including C<sub>max</sub> (18 ± 3.2 vs. 17.8 ± 3.4), AUC<sub>0-t</sub> (1,188.5 ± 222.2 vs. 1,170.9 ± 135.7), and AUC<sub>0-∞</sub> (1,353.3 ± 258.6 vs. 1,291.3 ± 136.7) values were assessed for bioequivalence based on current guidelines.",A bioequivalence study of two memantine formulations in healthy Chinese male volunteers . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28766500/),,"1,188.5",60390,DB00915,Amantadine
,28766500,AUC<sub>0-t</sub>,"The evaluated pharmacokinetic parameters (test vs. reference) including C<sub>max</sub> (18 ± 3.2 vs. 17.8 ± 3.4), AUC<sub>0-t</sub> (1,188.5 ± 222.2 vs. 1,170.9 ± 135.7), and AUC<sub>0-∞</sub> (1,353.3 ± 258.6 vs. 1,291.3 ± 136.7) values were assessed for bioequivalence based on current guidelines.",A bioequivalence study of two memantine formulations in healthy Chinese male volunteers . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28766500/),,"1,170.9",60391,DB00915,Amantadine
,28766500,AUC<sub>0-∞</sub>,"The evaluated pharmacokinetic parameters (test vs. reference) including C<sub>max</sub> (18 ± 3.2 vs. 17.8 ± 3.4), AUC<sub>0-t</sub> (1,188.5 ± 222.2 vs. 1,170.9 ± 135.7), and AUC<sub>0-∞</sub> (1,353.3 ± 258.6 vs. 1,291.3 ± 136.7) values were assessed for bioequivalence based on current guidelines.",A bioequivalence study of two memantine formulations in healthy Chinese male volunteers . ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28766500/),,"1,353.3",60392,DB00915,Amantadine
,28766500,AUC<sub>0-∞</sub>,"The evaluated pharmacokinetic parameters (test vs. reference) including C<sub>max</sub> (18 ± 3.2 vs. 17.8 ± 3.4), AUC<sub>0-t</sub> (1,188.5 ± 222.2 vs. 1,170.9 ± 135.7), and AUC<sub>0-∞</sub> (1,353.3 ± 258.6 vs. 1,291.3 ± 136.7) values were assessed for bioequivalence based on current guidelines.",A bioequivalence study of two memantine formulations in healthy Chinese male volunteers . ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28766500/),,"1,291.3",60393,DB00915,Amantadine
,21323678,apparent volume of distribution of the central compartment,"After i.v. administration, the apparent volume of distribution of the central compartment and apparent volume of distribution at steady-state [mean ± SEM (range)], and the clearance and terminal half-life [harmonic mean ± jackknife pseudo-SD (range)] were 1.5 ± 0.3 (0.7-2.5) L/kg, 4.3 ± 0.2 (3.7-5.0) L/kg, 8.2 ± 2.1 (5.9-11.4) mL·min/kg, and 348 ± 49 (307-465) min, respectively.",Pharmacokinetics of amantadine in cats. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21323678/),[l] / [kg],1.5,61020,DB00915,Amantadine
,21323678,apparent volume of distribution at steady-state,"After i.v. administration, the apparent volume of distribution of the central compartment and apparent volume of distribution at steady-state [mean ± SEM (range)], and the clearance and terminal half-life [harmonic mean ± jackknife pseudo-SD (range)] were 1.5 ± 0.3 (0.7-2.5) L/kg, 4.3 ± 0.2 (3.7-5.0) L/kg, 8.2 ± 2.1 (5.9-11.4) mL·min/kg, and 348 ± 49 (307-465) min, respectively.",Pharmacokinetics of amantadine in cats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21323678/),[l] / [kg],1.5,61021,DB00915,Amantadine
,21323678,apparent volume of distribution at steady-state,"After i.v. administration, the apparent volume of distribution of the central compartment and apparent volume of distribution at steady-state [mean ± SEM (range)], and the clearance and terminal half-life [harmonic mean ± jackknife pseudo-SD (range)] were 1.5 ± 0.3 (0.7-2.5) L/kg, 4.3 ± 0.2 (3.7-5.0) L/kg, 8.2 ± 2.1 (5.9-11.4) mL·min/kg, and 348 ± 49 (307-465) min, respectively.",Pharmacokinetics of amantadine in cats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21323678/),[l] / [kg],4.3,61022,DB00915,Amantadine
,21323678,clearance,"After i.v. administration, the apparent volume of distribution of the central compartment and apparent volume of distribution at steady-state [mean ± SEM (range)], and the clearance and terminal half-life [harmonic mean ± jackknife pseudo-SD (range)] were 1.5 ± 0.3 (0.7-2.5) L/kg, 4.3 ± 0.2 (3.7-5.0) L/kg, 8.2 ± 2.1 (5.9-11.4) mL·min/kg, and 348 ± 49 (307-465) min, respectively.",Pharmacokinetics of amantadine in cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21323678/),[l] / [kg],1.5,61023,DB00915,Amantadine
,21323678,clearance,"After i.v. administration, the apparent volume of distribution of the central compartment and apparent volume of distribution at steady-state [mean ± SEM (range)], and the clearance and terminal half-life [harmonic mean ± jackknife pseudo-SD (range)] were 1.5 ± 0.3 (0.7-2.5) L/kg, 4.3 ± 0.2 (3.7-5.0) L/kg, 8.2 ± 2.1 (5.9-11.4) mL·min/kg, and 348 ± 49 (307-465) min, respectively.",Pharmacokinetics of amantadine in cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21323678/),[l] / [kg],4.3,61024,DB00915,Amantadine
,21323678,terminal half-life,"After i.v. administration, the apparent volume of distribution of the central compartment and apparent volume of distribution at steady-state [mean ± SEM (range)], and the clearance and terminal half-life [harmonic mean ± jackknife pseudo-SD (range)] were 1.5 ± 0.3 (0.7-2.5) L/kg, 4.3 ± 0.2 (3.7-5.0) L/kg, 8.2 ± 2.1 (5.9-11.4) mL·min/kg, and 348 ± 49 (307-465) min, respectively.",Pharmacokinetics of amantadine in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21323678/),min,348,61025,DB00915,Amantadine
,21323678,Systemic availability,"Systemic availability [mean ± SEM (range)] and terminal half-life after oral administration [harmonic mean ± jackknife pseudo-SD (range)] were 130 ± 11 (86-160)% and 324 ± 41 (277-381) min, respectively.",Pharmacokinetics of amantadine in cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21323678/),%,130,61026,DB00915,Amantadine
,21323678,terminal half-life,"Systemic availability [mean ± SEM (range)] and terminal half-life after oral administration [harmonic mean ± jackknife pseudo-SD (range)] were 130 ± 11 (86-160)% and 324 ± 41 (277-381) min, respectively.",Pharmacokinetics of amantadine in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21323678/),min,324,61027,DB00915,Amantadine
,31342404,Renal clearance,"Renal clearance decreased from 10,965 to 2618 mL/h in subjects with severe renal impairment compared to those with normal renal function.",Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31342404/),[ml] / [h],"10,965",63082,DB00915,Amantadine
,31342404,Renal clearance,"Renal clearance decreased from 10,965 to 2618 mL/h in subjects with severe renal impairment compared to those with normal renal function.",Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31342404/),[ml] / [h],2618,63083,DB00915,Amantadine
,20697713,C (max),The mean C (max) and AUC values of plasma platinum observed after administration of LA-12 were from 0.84 to 2.5 mg/l and from 20.2 to 75.9 mg h/l.,"A comparative study of pharmacokinetics, urinary excretion and tissue distribution of platinum in rats following a single-dose oral administration of two platinum(IV) complexes LA-12 (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV) and satraplatin (OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum(IV). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20697713/),[mg] / [l],0.84 to 2.5,63704,DB00915,Amantadine
,20697713,AUC,The mean C (max) and AUC values of plasma platinum observed after administration of LA-12 were from 0.84 to 2.5 mg/l and from 20.2 to 75.9 mg h/l.,"A comparative study of pharmacokinetics, urinary excretion and tissue distribution of platinum in rats following a single-dose oral administration of two platinum(IV) complexes LA-12 (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV) and satraplatin (OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum(IV). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20697713/),[h·mg] / [l],20.2 to 75.9,63705,DB00915,Amantadine
,18814193,total chromatographic run time,"The total chromatographic run time was 3.0 min and the elution of PPX and IS occurred at approximately 2.32 and 2.52, respectively.",Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of pramipexole in human plasma: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18814193/),min,3.0,63947,DB00915,Amantadine
,18814193,ion transitions,The MS/MS ion transitions monitored were 212.10 --> 153.10 for PPX and 180.20 --> 107.30 for IS.,Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of pramipexole in human plasma: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18814193/),,212.10,63948,DB00915,Amantadine
,18814193,ion transitions,The MS/MS ion transitions monitored were 212.10 --> 153.10 for PPX and 180.20 --> 107.30 for IS.,Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of pramipexole in human plasma: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18814193/),,153.10,63949,DB00915,Amantadine
,18814193,ion transitions,The MS/MS ion transitions monitored were 212.10 --> 153.10 for PPX and 180.20 --> 107.30 for IS.,Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of pramipexole in human plasma: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18814193/),,180.20,63950,DB00915,Amantadine
,18589560,half-lives,The findings suggest that even for drugs with half-lives between 24 and 60 h and thus shorter than those of donepezil and memantine an AUC truncated to 48 h post dose can be successfully used for the assessment of bioequivalence as this sample collection time ensures a proper comparison of the absorption process as recommended in the CPMP Note for Guidance on the Investigation of Bioavailability and Bioequivalence.,The use of truncated area under the curves in the bioequivalence evaluation of long half-life drugs. Studies with donepezil and memantine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18589560/),h,24 and 60,79119,DB00915,Amantadine
,25573540,binding affinity,The altered pharmacokinetics of a synthetic ozonide in rats has been attributed to an unusually high-binding affinity (2.3 × 10(6) M(-1) ) between the drug and sulfobutylether7 -β-cyclodextrin (SBE7 -β-CD) with further studies suggesting a significant binding contribution from the adamantane ring.,The effect of intravenous sulfobutylether7 -β-cyclodextrin on the pharmacokinetics of a series of adamantane-containing compounds. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573540/),1/[M],2.3 × 10(6),82026,DB00915,Amantadine
,25573540,binding constants,SBE7 -β-CD binding constants for the compounds were within the typical range for drug-like molecules (10(2) -10(4) M(-1) ).,The effect of intravenous sulfobutylether7 -β-cyclodextrin on the pharmacokinetics of a series of adamantane-containing compounds. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573540/),1/[M],10(2) -10(4),82027,DB00915,Amantadine
,1771145,steady-state trough serum concentrations (CPSSt),We sought to determine if a standard daily dose of 50 mg would achieve mean steady-state trough serum concentrations (CPSSt) of 300 ng/ml and be associated with a lower frequency of adverse events than 100-mg doses.,Comparison of pharmacokinetic and safety profiles of amantadine 50- and 100-mg daily doses in elderly nursing home residents. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771145/),[ng] / [ml],300,87180,DB00915,Amantadine
below,1771145,CPSSt,Thirty-nine residents (89%) receiving 50 mg daily achieved CPSSt below 300 ng/ml compared to 42% receiving 100 mg.,Comparison of pharmacokinetic and safety profiles of amantadine 50- and 100-mg daily doses in elderly nursing home residents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771145/),[ng] / [ml],300,87181,DB00915,Amantadine
,18316252,total analytical run time,"The total analytical run time was relatively short (4.6 min), and the limit of assay quantification (LLOQ) was 2 ng/mL using 50 microL of rat plasma.",Determination of rimantadine in rat plasma by liquid chromatography/electrospray mass spectrometry and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18316252/),min,4.6,92647,DB00915,Amantadine
,3252751,elimination half-life,"Maximum concentrations in plasma occurred at less than 0.5 h after oral administration, and the elimination half-life was 1.5 h.",Pharmacokinetics and metabolism of rimantadine hydrochloride in mice and dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252751/),h,1.5,95002,DB00915,Amantadine
,3252751,Peak concentrations,"Peak concentrations in plasma following oral administration were markedly disproportional to the dose (274 ng/ml at 10 mg/kg, but 2,013 ng/ml at 40 mg/kg).",Pharmacokinetics and metabolism of rimantadine hydrochloride in mice and dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252751/),[ng] / [ml],274,95003,DB00915,Amantadine
,3252751,Peak concentrations,"Peak concentrations in plasma following oral administration were markedly disproportional to the dose (274 ng/ml at 10 mg/kg, but 2,013 ng/ml at 40 mg/kg).",Pharmacokinetics and metabolism of rimantadine hydrochloride in mice and dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252751/),[ng] / [ml],"2,013",95004,DB00915,Amantadine
,3252751,bioavailability,The bioavailability after an oral dose of 40 mg/kg was 58.6%.,Pharmacokinetics and metabolism of rimantadine hydrochloride in mice and dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252751/),%,58.6,95005,DB00915,Amantadine
,3252751,Clearance,"Clearance was 4.3 liters/h per kg, and the volume of distribution was 7.6 liters/kg at 40 mg/kg.",Pharmacokinetics and metabolism of rimantadine hydrochloride in mice and dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252751/),[l] / [h·kg],4.3,95006,DB00915,Amantadine
,3252751,volume of distribution,"Clearance was 4.3 liters/h per kg, and the volume of distribution was 7.6 liters/kg at 40 mg/kg.",Pharmacokinetics and metabolism of rimantadine hydrochloride in mice and dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252751/),[l] / [kg],7.6,95007,DB00915,Amantadine
,3252751,elimination half-life,"Maximum concentrations in plasma occurred at 1.7 h after oral administration, and the elimination half-life was 3.3 h.",Pharmacokinetics and metabolism of rimantadine hydrochloride in mice and dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252751/),h,3.3,95008,DB00915,Amantadine
,3252751,maximum concentrations,"Following administration of a single oral dose of 5, 10, or 20 mg/kg, maximum concentrations in plasma were 275,800, and 1,950 ng/ml, respectively.",Pharmacokinetics and metabolism of rimantadine hydrochloride in mice and dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252751/),[ng] / [ml],275,95009,DB00915,Amantadine
,3252751,maximum concentrations,"Following administration of a single oral dose of 5, 10, or 20 mg/kg, maximum concentrations in plasma were 275,800, and 1,950 ng/ml, respectively.",Pharmacokinetics and metabolism of rimantadine hydrochloride in mice and dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252751/),[ng] / [ml],800,95010,DB00915,Amantadine
,3252751,maximum concentrations,"Following administration of a single oral dose of 5, 10, or 20 mg/kg, maximum concentrations in plasma were 275,800, and 1,950 ng/ml, respectively.",Pharmacokinetics and metabolism of rimantadine hydrochloride in mice and dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252751/),[ng] / [ml],"1,950",95011,DB00915,Amantadine
,3252751,bioavailability,The bioavailability after an oral dose of 5 mg/kg was 99.4%.,Pharmacokinetics and metabolism of rimantadine hydrochloride in mice and dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252751/),%,99.4,95012,DB00915,Amantadine
,3252751,clearance,"The clearance was 3.7 liters/h per kg, and the volume of distribution was 13.8 liters/kg at 5 mg/kg.",Pharmacokinetics and metabolism of rimantadine hydrochloride in mice and dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252751/),[l] / [h·kg],3.7,95013,DB00915,Amantadine
,3252751,volume of distribution,"The clearance was 3.7 liters/h per kg, and the volume of distribution was 13.8 liters/kg at 5 mg/kg.",Pharmacokinetics and metabolism of rimantadine hydrochloride in mice and dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252751/),[l] / [kg],13.8,95014,DB00915,Amantadine
,31978146,DF,"Single dose of memantine significantly increased DF, from basic values (1.65±1.05 cycles per min.) to 2.86 cpm after 30 min.",The pharmacokinetic parameters and the effect of a single and repeated doses of memantine on gastric myoelectric activity in experimental pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31978146/),[cycles] / [min],1.65,95293,DB00915,Amantadine
,31978146,DF,"Single dose of memantine significantly increased DF, from basic values (1.65±1.05 cycles per min.) to 2.86 cpm after 30 min.",The pharmacokinetic parameters and the effect of a single and repeated doses of memantine on gastric myoelectric activity in experimental pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31978146/),cpm,2.86,95294,DB00915,Amantadine
,31978146,basal power,"In comparison with a single dose, basal power was significantly higher after repetitively administrated memantine (median 3940; IQR 695-15023 μV^2; p<0.001).",The pharmacokinetic parameters and the effect of a single and repeated doses of memantine on gastric myoelectric activity in experimental pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31978146/),μv^2,3940,95295,DB00915,Amantadine
,23513957,LOD,"LOD and LOQ were found to be 0.3 and 1.0 ng/mL, respectively.",A new HPLC method with fluorescence detection for the determination of memantine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23513957/),[ng] / [ml],0.3,96263,DB00915,Amantadine
,23513957,LOQ,"LOD and LOQ were found to be 0.3 and 1.0 ng/mL, respectively.",A new HPLC method with fluorescence detection for the determination of memantine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23513957/),[ng] / [ml],1.0,96264,DB00915,Amantadine
,21594878,signal-to-noise ratios,"The limits of detection and quantitation at signal-to-noise ratios of 3 and 10 were 2.0 and 6.6 ng/mL, respectively.",Determination of memantine in rat plasma by HPLC-fluorescence method and its application to study of the pharmacokinetic interaction between memantine and methazolamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21594878/),[ng] / [ml],3,99760,DB00915,Amantadine
,21594878,signal-to-noise ratios,"The limits of detection and quantitation at signal-to-noise ratios of 3 and 10 were 2.0 and 6.6 ng/mL, respectively.",Determination of memantine in rat plasma by HPLC-fluorescence method and its application to study of the pharmacokinetic interaction between memantine and methazolamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21594878/),[ng] / [ml],10,99761,DB00915,Amantadine
,21594878,signal-to-noise ratios,"The limits of detection and quantitation at signal-to-noise ratios of 3 and 10 were 2.0 and 6.6 ng/mL, respectively.",Determination of memantine in rat plasma by HPLC-fluorescence method and its application to study of the pharmacokinetic interaction between memantine and methazolamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21594878/),[ng] / [ml],2.0,99762,DB00915,Amantadine
,21594878,signal-to-noise ratios,"The limits of detection and quantitation at signal-to-noise ratios of 3 and 10 were 2.0 and 6.6 ng/mL, respectively.",Determination of memantine in rat plasma by HPLC-fluorescence method and its application to study of the pharmacokinetic interaction between memantine and methazolamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21594878/),[ng] / [ml],6.6,99763,DB00915,Amantadine
,7035042,Plasma half-life,"Plasma half-life averaged 68.5 +/- 9.5 SEM hours in the renal patients (range: 27 to 144), versus 12.6 +/- 1.7 hours in controls.",Amantadine hydrochloride pharmacokinetics in patients with impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7035042/),h,68.5,101673,DB00915,Amantadine
,7035042,Plasma half-life,"Plasma half-life averaged 68.5 +/- 9.5 SEM hours in the renal patients (range: 27 to 144), versus 12.6 +/- 1.7 hours in controls.",Amantadine hydrochloride pharmacokinetics in patients with impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7035042/),h,12.6,101674,DB00915,Amantadine
,3834831,peak plasma concentration,"For both groups combined, rimantadine differed significantly from amantadine in peak plasma concentration (mean +/- standard deviation, 0.25 +/- 0.06 versus 0.65 +/- 0.22 micrograms/ml), plasma elimination half-life (36.5 +/- 15 versus 16.7 +/- 7.7 h), and percentage of administered dose excreted unchanged in urine (0.6 +/- 0.8 versus 45.7 +/- 15.7%).",Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3834831/),[μg] / [ml],0.25,103256,DB00915,Amantadine
,3834831,peak plasma concentration,"For both groups combined, rimantadine differed significantly from amantadine in peak plasma concentration (mean +/- standard deviation, 0.25 +/- 0.06 versus 0.65 +/- 0.22 micrograms/ml), plasma elimination half-life (36.5 +/- 15 versus 16.7 +/- 7.7 h), and percentage of administered dose excreted unchanged in urine (0.6 +/- 0.8 versus 45.7 +/- 15.7%).",Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3834831/),[μg] / [ml],0.65,103257,DB00915,Amantadine
,3834831,plasma elimination half-life,"For both groups combined, rimantadine differed significantly from amantadine in peak plasma concentration (mean +/- standard deviation, 0.25 +/- 0.06 versus 0.65 +/- 0.22 micrograms/ml), plasma elimination half-life (36.5 +/- 15 versus 16.7 +/- 7.7 h), and percentage of administered dose excreted unchanged in urine (0.6 +/- 0.8 versus 45.7 +/- 15.7%).",Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3834831/),h,36.5,103258,DB00915,Amantadine
,3834831,plasma elimination half-life,"For both groups combined, rimantadine differed significantly from amantadine in peak plasma concentration (mean +/- standard deviation, 0.25 +/- 0.06 versus 0.65 +/- 0.22 micrograms/ml), plasma elimination half-life (36.5 +/- 15 versus 16.7 +/- 7.7 h), and percentage of administered dose excreted unchanged in urine (0.6 +/- 0.8 versus 45.7 +/- 15.7%).",Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3834831/),h,16.7,103259,DB00915,Amantadine
,3834831,percentage of administered dose excreted unchanged,"For both groups combined, rimantadine differed significantly from amantadine in peak plasma concentration (mean +/- standard deviation, 0.25 +/- 0.06 versus 0.65 +/- 0.22 micrograms/ml), plasma elimination half-life (36.5 +/- 15 versus 16.7 +/- 7.7 h), and percentage of administered dose excreted unchanged in urine (0.6 +/- 0.8 versus 45.7 +/- 15.7%).",Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3834831/),%,0.6,103260,DB00915,Amantadine
,3834831,percentage of administered dose excreted unchanged,"For both groups combined, rimantadine differed significantly from amantadine in peak plasma concentration (mean +/- standard deviation, 0.25 +/- 0.06 versus 0.65 +/- 0.22 micrograms/ml), plasma elimination half-life (36.5 +/- 15 versus 16.7 +/- 7.7 h), and percentage of administered dose excreted unchanged in urine (0.6 +/- 0.8 versus 45.7 +/- 15.7%).",Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3834831/),%,45.7,103261,DB00915,Amantadine
,3834831,maximum nasal mucus drug concentration,"The maximum nasal mucus drug concentration was similar for both drugs (0.42 +/- 0.25 versus 0.45 +/- 0.32 micrograms/g), and the ratio of maximum nasal mucus to plasma concentration was over twofold higher after rimantadine than after amantadine.",Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3834831/),[μg] / [g],0.42,103262,DB00915,Amantadine
,3834831,maximum nasal mucus drug concentration,"The maximum nasal mucus drug concentration was similar for both drugs (0.42 +/- 0.25 versus 0.45 +/- 0.32 micrograms/g), and the ratio of maximum nasal mucus to plasma concentration was over twofold higher after rimantadine than after amantadine.",Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3834831/),[μg] / [g],0.45,103263,DB00915,Amantadine
,17156962,extraction efficiencies,The extraction efficiencies were approximately 70% and recoveries of method ranged from 98.53 to 103.24%.,Quantitative determination of amantadine in human plasma by liquid chromatography-mass spectrometry and the application in a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17156962/),%,70,107736,DB00915,Amantadine
,17156962,recoveries,The extraction efficiencies were approximately 70% and recoveries of method ranged from 98.53 to 103.24%.,Quantitative determination of amantadine in human plasma by liquid chromatography-mass spectrometry and the application in a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17156962/),%,98.53 to 103.24,107737,DB00915,Amantadine
,3967456,trough steady-state plasma amantadine concentration (Cpss,We calculated a dose that would yield the same trough steady-state plasma amantadine concentration (Cpss; 300 ng/ml) as a 200 mg/day dose taken by young healthy adults; this dose prevents influenza A virus infection and is well tolerated by this population.,Amantadine kinetics in healthy elderly men: implications for influenza prevention. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3967456/),[ng] / [ml],300,107772,DB00915,Amantadine
,3967456,t1/2,"There was first-order elimination of drug from plasma, with a median t1/2 of 28.9 hr (range 18.5 to 45.0 hr), and elimination was independent of dose and creatinine clearance.",Amantadine kinetics in healthy elderly men: implications for influenza prevention. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3967456/),h,28.9,107773,DB00915,Amantadine
,3967456,trough Cpss,"To achieve the target trough Cpss of 300 ng/ml, healthy older men must take amantadine at a dose of 1.4 mg/kg/day, and we suggest that this is a rational dose for evaluation of efficacy and safety for influenza A prophylaxis in this population.",Amantadine kinetics in healthy elderly men: implications for influenza prevention. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3967456/),[ng] / [ml],300,107774,DB00915,Amantadine
,18435468,AUC(0-12h),"Patients with a SVR had a significantly higher D0 AUC(0-12h) (3695 [1571-6916] versus 2937 [1266-4913] microg/hour/L, P = 0.03) and D0 AUC(0-4h) (2010 [615-3175] versus 1340 [622-2246] microg/hour/L, P = 0.03).",Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18435468/),[μg] / [h·l],3695,109978,DB00915,Amantadine
,18435468,AUC(0-12h),"Patients with a SVR had a significantly higher D0 AUC(0-12h) (3695 [1571-6916] versus 2937 [1266-4913] microg/hour/L, P = 0.03) and D0 AUC(0-4h) (2010 [615-3175] versus 1340 [622-2246] microg/hour/L, P = 0.03).",Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18435468/),[μg] / [h·l],2937,109979,DB00915,Amantadine
,18435468,AUC(0-4h),"Patients with a SVR had a significantly higher D0 AUC(0-12h) (3695 [1571-6916] versus 2937 [1266-4913] microg/hour/L, P = 0.03) and D0 AUC(0-4h) (2010 [615-3175] versus 1340 [622-2246] microg/hour/L, P = 0.03).",Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18435468/),[μg] / [h·l],2010,109980,DB00915,Amantadine
,18435468,AUC(0-4h),"Patients with a SVR had a significantly higher D0 AUC(0-12h) (3695 [1571-6916] versus 2937 [1266-4913] microg/hour/L, P = 0.03) and D0 AUC(0-4h) (2010 [615-3175] versus 1340 [622-2246] microg/hour/L, P = 0.03).",Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18435468/),[μg] / [h·l],1340,109981,DB00915,Amantadine
,18435468,AUCs,"Patients with D0 AUCs above the cut-off values defined by receiver operating characteristic curves (3014 microg/hour/L and 1755 microg/hour/L for AUC(0-12h) and AUC(0-4h), respectively) had a significantly better chance of achieving an SVR than patients with AUCs under the thresholds (odds ratio = 16.0, 95% confidence interval 1.54-166.6, P = 0.02 and odds ratio = 8.9, 95% confidence interval, 1.4-56.6; P = 0.02).",Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18435468/),[μg] / [h·l],3014,109982,DB00915,Amantadine
,18435468,AUCs,"Patients with D0 AUCs above the cut-off values defined by receiver operating characteristic curves (3014 microg/hour/L and 1755 microg/hour/L for AUC(0-12h) and AUC(0-4h), respectively) had a significantly better chance of achieving an SVR than patients with AUCs under the thresholds (odds ratio = 16.0, 95% confidence interval 1.54-166.6, P = 0.02 and odds ratio = 8.9, 95% confidence interval, 1.4-56.6; P = 0.02).",Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18435468/),[μg] / [h·l],1755,109983,DB00915,Amantadine
,18435468,AUC(0-12h),"Patients with D0 AUCs above the cut-off values defined by receiver operating characteristic curves (3014 microg/hour/L and 1755 microg/hour/L for AUC(0-12h) and AUC(0-4h), respectively) had a significantly better chance of achieving an SVR than patients with AUCs under the thresholds (odds ratio = 16.0, 95% confidence interval 1.54-166.6, P = 0.02 and odds ratio = 8.9, 95% confidence interval, 1.4-56.6; P = 0.02).",Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18435468/),[μg] / [h·l],3014,109984,DB00915,Amantadine
,18435468,AUC(0-12h),"Patients with D0 AUCs above the cut-off values defined by receiver operating characteristic curves (3014 microg/hour/L and 1755 microg/hour/L for AUC(0-12h) and AUC(0-4h), respectively) had a significantly better chance of achieving an SVR than patients with AUCs under the thresholds (odds ratio = 16.0, 95% confidence interval 1.54-166.6, P = 0.02 and odds ratio = 8.9, 95% confidence interval, 1.4-56.6; P = 0.02).",Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18435468/),[μg] / [h·l],1755,109985,DB00915,Amantadine
,18435468,AUC(0-4h),"Patients with D0 AUCs above the cut-off values defined by receiver operating characteristic curves (3014 microg/hour/L and 1755 microg/hour/L for AUC(0-12h) and AUC(0-4h), respectively) had a significantly better chance of achieving an SVR than patients with AUCs under the thresholds (odds ratio = 16.0, 95% confidence interval 1.54-166.6, P = 0.02 and odds ratio = 8.9, 95% confidence interval, 1.4-56.6; P = 0.02).",Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18435468/),[μg] / [h·l],1755,109986,DB00915,Amantadine
,18435468,AUC(0-4h),We propose a minimum AUC(0-4h) threshold of 1755 microg/hour/L at D0 as a target for ribavirin dose adjustment.,Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18435468/),[μg] / [h·l],1755,109987,DB00915,Amantadine
,15266045,Percent maximum inhibition,Percent maximum inhibition of AChE activity (mean +/- SD) by donepezil was 77.8 +/- 7.3% and not significantly different upon coadministration of a single dose of memantine (81.1 +/- 5.7%).,Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15266045/),%,77.8,110075,DB00915,Amantadine
,15266045,Percent maximum inhibition,Percent maximum inhibition of AChE activity (mean +/- SD) by donepezil was 77.8 +/- 7.3% and not significantly different upon coadministration of a single dose of memantine (81.1 +/- 5.7%).,Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15266045/),%,81.1,110076,DB00915,Amantadine
,15607264,C(max),"The mean C(max) values of 1.5 and 6.3 mg L(-1) were observed at 0.5 and 1 h, respectively, and the mean AUC values achieved were 29 and 144 mg h L(-1).",Pharmacokinetics and tissue distribution of platinum in rats following single and multiple oral doses of LA-12 [(OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15607264/),[mg] / [l],1.5,127117,DB00915,Amantadine
,15607264,C(max),"The mean C(max) values of 1.5 and 6.3 mg L(-1) were observed at 0.5 and 1 h, respectively, and the mean AUC values achieved were 29 and 144 mg h L(-1).",Pharmacokinetics and tissue distribution of platinum in rats following single and multiple oral doses of LA-12 [(OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15607264/),[mg] / [l],6.3,127118,DB00915,Amantadine
,15607264,AUC,"The mean C(max) values of 1.5 and 6.3 mg L(-1) were observed at 0.5 and 1 h, respectively, and the mean AUC values achieved were 29 and 144 mg h L(-1).",Pharmacokinetics and tissue distribution of platinum in rats following single and multiple oral doses of LA-12 [(OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV)]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15607264/),[h·mg] / [l],29,127119,DB00915,Amantadine
,15607264,AUC,"The mean C(max) values of 1.5 and 6.3 mg L(-1) were observed at 0.5 and 1 h, respectively, and the mean AUC values achieved were 29 and 144 mg h L(-1).",Pharmacokinetics and tissue distribution of platinum in rats following single and multiple oral doses of LA-12 [(OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV)]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15607264/),[h·mg] / [l],144,127120,DB00915,Amantadine
,15607264,initial half-life,Concentrations of Pt in the plasma ultrafiltrate decreased rapidly with the initial half-life of 1 h.,Pharmacokinetics and tissue distribution of platinum in rats following single and multiple oral doses of LA-12 [(OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15607264/),h,1,127121,DB00915,Amantadine
,24597794,relative,"High vitreous bioavailability after PST was observed, and the relative vitreous bioavailability of memantine following PST administration (0.53%) was greater than for intravenous administration (0.02%).","Vitreous pharmacokinetics and bioavailability of memantine after subtenon, intravenous, and intravitreal administration in rabbits. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24597794/),%,0.53,135803,DB00915,Amantadine
,24597794,relative,"High vitreous bioavailability after PST was observed, and the relative vitreous bioavailability of memantine following PST administration (0.53%) was greater than for intravenous administration (0.02%).","Vitreous pharmacokinetics and bioavailability of memantine after subtenon, intravenous, and intravitreal administration in rabbits. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24597794/),%,0.02,135804,DB00915,Amantadine
,16413248,steady-state maximum concentration,"Simulations predicted steady-state maximum concentration values of 82 ng/mL (95% CI, 70-95 ng/mL), 85 ng/mL (95% CI, 70-101 ng/mL), and 128 ng/mL (95% CI, 109-147 ng/mL) in healthy subjects, those with mild renal impairment, and those with moderate renal impairment, respectively, for the recommended dosing regimen of 10 mg twice daily; for subjects with severe renal impairment, a steady-state maximum concentration value of 84 ng/mL (95% CI, 68-101 ng/mL) was predicted for a dosing regimen of 5 mg twice daily.",Pharmacokinetic study of memantine in healthy and renally impaired subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413248/),[ng] / [ml],82,150674,DB00915,Amantadine
,16413248,steady-state maximum concentration,"Simulations predicted steady-state maximum concentration values of 82 ng/mL (95% CI, 70-95 ng/mL), 85 ng/mL (95% CI, 70-101 ng/mL), and 128 ng/mL (95% CI, 109-147 ng/mL) in healthy subjects, those with mild renal impairment, and those with moderate renal impairment, respectively, for the recommended dosing regimen of 10 mg twice daily; for subjects with severe renal impairment, a steady-state maximum concentration value of 84 ng/mL (95% CI, 68-101 ng/mL) was predicted for a dosing regimen of 5 mg twice daily.",Pharmacokinetic study of memantine in healthy and renally impaired subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413248/),[ng] / [ml],85,150675,DB00915,Amantadine
,16413248,steady-state maximum concentration,"Simulations predicted steady-state maximum concentration values of 82 ng/mL (95% CI, 70-95 ng/mL), 85 ng/mL (95% CI, 70-101 ng/mL), and 128 ng/mL (95% CI, 109-147 ng/mL) in healthy subjects, those with mild renal impairment, and those with moderate renal impairment, respectively, for the recommended dosing regimen of 10 mg twice daily; for subjects with severe renal impairment, a steady-state maximum concentration value of 84 ng/mL (95% CI, 68-101 ng/mL) was predicted for a dosing regimen of 5 mg twice daily.",Pharmacokinetic study of memantine in healthy and renally impaired subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413248/),[ng] / [ml],128,150676,DB00915,Amantadine
,16413248,steady-state maximum concentration,"Simulations predicted steady-state maximum concentration values of 82 ng/mL (95% CI, 70-95 ng/mL), 85 ng/mL (95% CI, 70-101 ng/mL), and 128 ng/mL (95% CI, 109-147 ng/mL) in healthy subjects, those with mild renal impairment, and those with moderate renal impairment, respectively, for the recommended dosing regimen of 10 mg twice daily; for subjects with severe renal impairment, a steady-state maximum concentration value of 84 ng/mL (95% CI, 68-101 ng/mL) was predicted for a dosing regimen of 5 mg twice daily.",Pharmacokinetic study of memantine in healthy and renally impaired subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413248/),[ng] / [ml],84,150677,DB00915,Amantadine
,10411561,half-life,In serum the half-life of MRZ 2/576 (30 mg/kg) was also increased by coadministration of probenecid from 15.6 +/- 1.3 to 40.6 +/- 6.0 min.,The role of probenecid-sensitive organic acid transport in the pharmacokinetics of N-methyl-D-aspartate receptor antagonists acting at the glycine(B)-site: microdialysis and maximum electroshock seizures studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10411561/),min,15.6,156588,DB00915,Amantadine
,10411561,half-life,In serum the half-life of MRZ 2/576 (30 mg/kg) was also increased by coadministration of probenecid from 15.6 +/- 1.3 to 40.6 +/- 6.0 min.,The role of probenecid-sensitive organic acid transport in the pharmacokinetics of N-methyl-D-aspartate receptor antagonists acting at the glycine(B)-site: microdialysis and maximum electroshock seizures studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10411561/),min,40.6,156589,DB00915,Amantadine
,17103338,rate of perfusion,"Fresh bovine eyes were prepared by exposing and cannulating one ciliary artery, placing the eye into a perfusion chamber and slowly increasing the rate of perfusion to 1.0 ml/min.",Pharmacokinetics and disposition of memantine in the arterially perfused bovine eye. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17103338/),[ml] / [min],1.0,158845,DB00915,Amantadine
,21179320,flow rate,"The mobile phase was composed of a mixture of acetonitrile and 0.025 M phosphate buffer (50:50, v/v, pH=4.6) with a flow rate of 2.5 mLmin(â1).",Sensitive and rapid HPLC method for determination of memantine in human plasma using OPA derivatization and fluorescence detection: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21179320/),mlmin(â1),2.5,168136,DB00915,Amantadine
,21179320,analytical recovery,The method involves simple extraction procedure and analytical recovery was 82.8Â 0.9%.,Sensitive and rapid HPLC method for determination of memantine in human plasma using OPA derivatization and fluorescence detection: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21179320/),%,82.8,168137,DB00915,Amantadine
,7396313,Apparent volume of distribution,Apparent volume of distribution was 5.1 +/- 0.2 (SEM) L/kg of body weight.,Amantadine hydrochloride pharmacokinetics in hemodialysis patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7396313/),[l] / [kg],5.1,171495,DB00915,Amantadine
,7396313,clearance,Dialyzer clearance was 67.0 +/- 3.9 mL of plasma per minute.,Amantadine hydrochloride pharmacokinetics in hemodialysis patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7396313/),[ml·plasma] / [min],67.0,171496,DB00915,Amantadine
,7396313,total quantity of drug removed,"The total quantity of drug removed by the dialysis treatment, however, was only 3.9 +/- 0.25 mg.",Amantadine hydrochloride pharmacokinetics in hemodialysis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7396313/),mg,3.9,171497,DB00915,Amantadine
,7396313,half-life,The average half-life of amantadine in eight patients studied while receiving maintenance hemodialysis was 24.3 +/- 2.4 h of dialysis administered over approximately 13 days.,Amantadine hydrochloride pharmacokinetics in hemodialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7396313/),h,24.3,171498,DB00915,Amantadine
,7396313,Plasma half-life,Plasma half-life in six nonuremic control subjects was 12.2 +/- 1.6 h.,Amantadine hydrochloride pharmacokinetics in hemodialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7396313/),h,12.2,171499,DB00915,Amantadine
,7813574,time to reach this maximum (tmax),"The maximal concentrations (Cmax) differed dose dependently, whereas the time to reach this maximum (tmax) was almost identical (68.5 +/- 3.4 min).",Memantine-induced dopamine release in the prefrontal cortex and striatum of the rat--a pharmacokinetic microdialysis study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7813574/),min,68.5,172840,DB00915,Amantadine
,7813574,half-life,From the flat elimination profile a half-life of 2.8 +/- 0.5 h (range 2-3.4 h) was calculated.,Memantine-induced dopamine release in the prefrontal cortex and striatum of the rat--a pharmacokinetic microdialysis study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7813574/),h,2.8,172841,DB00915,Amantadine
,30087157,EC50,Outcomes from each of the species evaluated indicate that the EC50 of amantadine for reducing dyskinesia range from 1025 to 1633 ng/ml (1367 ng/ml for an all-species model).,Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced Dyskinesia. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30087157/),[ng] / [ml],1025 to 1633,172850,DB00915,Amantadine
,30087157,EC50,Outcomes from each of the species evaluated indicate that the EC50 of amantadine for reducing dyskinesia range from 1025 to 1633 ng/ml (1367 ng/ml for an all-species model).,Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced Dyskinesia. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30087157/),[ng] / [ml],1367,172851,DB00915,Amantadine
,29777529,time to maximum concentration,"Single ADS-5102 doses resulted in a slow initial rise in amantadine plasma concentration, with delayed time to maximum concentration (12-16 h).",Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29777529/),h,12-16,180380,DB00915,Amantadine
,9104558,minimum plasma concentration,Rimantadine was more effective than amantadine against most viral isolates; we suggest a minimum plasma concentration of 300 ng/ml of amantadine for therapeutic efficacy.,"Amantadine and equine influenza: pharmacology, pharmacokinetics and neurological effects in the horse. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9104558/),[ng] / [ml],300,181250,DB00915,Amantadine
greater,9104558,maximal safe plasma concentration,The maximal safe plasma concentration of amantadine was not evaluated but is probably greater than 2000 ng/ml and possibly greater than 4000 ng/ml.,"Amantadine and equine influenza: pharmacology, pharmacokinetics and neurological effects in the horse. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9104558/),[ng] / [ml],2000,181251,DB00915,Amantadine
greater,9104558,maximal safe plasma concentration,The maximal safe plasma concentration of amantadine was not evaluated but is probably greater than 2000 ng/ml and possibly greater than 4000 ng/ml.,"Amantadine and equine influenza: pharmacology, pharmacokinetics and neurological effects in the horse. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9104558/),[ng] / [ml],4000,181252,DB00915,Amantadine
,9104558,peak plasma concentration,"The estimated peak plasma concentration after this dose was about 4500 ng/ml, the volume of distribution at steady-state (Vdss) was (mean +/- s.d.) 4.9 +/- 1.9 l/kg bwt and the beta phase half-life was 1.83 +/- 0.87 h.","Amantadine and equine influenza: pharmacology, pharmacokinetics and neurological effects in the horse. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9104558/),[ng] / [ml],4500,181253,DB00915,Amantadine
,9104558,volume of distribution at steady-state (Vdss),"The estimated peak plasma concentration after this dose was about 4500 ng/ml, the volume of distribution at steady-state (Vdss) was (mean +/- s.d.) 4.9 +/- 1.9 l/kg bwt and the beta phase half-life was 1.83 +/- 0.87 h.","Amantadine and equine influenza: pharmacology, pharmacokinetics and neurological effects in the horse. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9104558/),[l] / [bwt·kg],4.9,181254,DB00915,Amantadine
,9104558,beta phase half-life,"The estimated peak plasma concentration after this dose was about 4500 ng/ml, the volume of distribution at steady-state (Vdss) was (mean +/- s.d.) 4.9 +/- 1.9 l/kg bwt and the beta phase half-life was 1.83 +/- 0.87 h.","Amantadine and equine influenza: pharmacology, pharmacokinetics and neurological effects in the horse. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9104558/),h,1.83,181255,DB00915,Amantadine
,9104558,peak plasma concentrations,Computer projections of plasma amantadine concentrations after i.v. administration of amantadine at a dose of 10 mg/kg bwt t.i.d. at 8 h intervals suggest peak plasma concentrations of 4000-5000 ng/ml and troughs of less than 300 ng/ml will be achieved.,"Amantadine and equine influenza: pharmacology, pharmacokinetics and neurological effects in the horse. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9104558/),[ng] / [ml],4000-5000,181256,DB00915,Amantadine
less,9104558,troughs,Computer projections of plasma amantadine concentrations after i.v. administration of amantadine at a dose of 10 mg/kg bwt t.i.d. at 8 h intervals suggest peak plasma concentrations of 4000-5000 ng/ml and troughs of less than 300 ng/ml will be achieved.,"Amantadine and equine influenza: pharmacology, pharmacokinetics and neurological effects in the horse. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9104558/),[ng] / [ml],300,181257,DB00915,Amantadine
,9104558,oral bioavailability,"Amantadine administered orally at 10 mg/kg bwt and 20 mg/kg bwt showed mean oral bioavailability of about 40-60% and a plasma half life of 3.4 +/- 1.4 h; however, there was substantial inter-animal variation in bioavailability.","Amantadine and equine influenza: pharmacology, pharmacokinetics and neurological effects in the horse. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9104558/),%,40-60,181258,DB00915,Amantadine
,9104558,plasma half life,"Amantadine administered orally at 10 mg/kg bwt and 20 mg/kg bwt showed mean oral bioavailability of about 40-60% and a plasma half life of 3.4 +/- 1.4 h; however, there was substantial inter-animal variation in bioavailability.","Amantadine and equine influenza: pharmacology, pharmacokinetics and neurological effects in the horse. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9104558/),h,3.4,181259,DB00915,Amantadine
,22863669,maximum plasma concentration (C(max)),"Mean memantine maximum plasma concentration (C(max)) was similar in the groups (12.66, 17.25, 15.75, and 15.83 ng/mL, respectively), as was mean time to C(max) (6.2, 5.2, 4.3, and 5.4 h, respectively).",Effect of renal impairment on the pharmacokinetics of memantine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22863669/),[ng] / [ml],12.66,181989,DB00915,Amantadine
,22863669,maximum plasma concentration (C(max)),"Mean memantine maximum plasma concentration (C(max)) was similar in the groups (12.66, 17.25, 15.75, and 15.83 ng/mL, respectively), as was mean time to C(max) (6.2, 5.2, 4.3, and 5.4 h, respectively).",Effect of renal impairment on the pharmacokinetics of memantine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22863669/),[ng] / [ml],17.25,181990,DB00915,Amantadine
,22863669,maximum plasma concentration (C(max)),"Mean memantine maximum plasma concentration (C(max)) was similar in the groups (12.66, 17.25, 15.75, and 15.83 ng/mL, respectively), as was mean time to C(max) (6.2, 5.2, 4.3, and 5.4 h, respectively).",Effect of renal impairment on the pharmacokinetics of memantine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22863669/),[ng] / [ml],15.75,181991,DB00915,Amantadine
,22863669,maximum plasma concentration (C(max)),"Mean memantine maximum plasma concentration (C(max)) was similar in the groups (12.66, 17.25, 15.75, and 15.83 ng/mL, respectively), as was mean time to C(max) (6.2, 5.2, 4.3, and 5.4 h, respectively).",Effect of renal impairment on the pharmacokinetics of memantine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22863669/),[ng] / [ml],15.83,181992,DB00915,Amantadine
,22863669,time to C(max),"Mean memantine maximum plasma concentration (C(max)) was similar in the groups (12.66, 17.25, 15.75, and 15.83 ng/mL, respectively), as was mean time to C(max) (6.2, 5.2, 4.3, and 5.4 h, respectively).",Effect of renal impairment on the pharmacokinetics of memantine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22863669/),h,6.2,181993,DB00915,Amantadine
,22863669,time to C(max),"Mean memantine maximum plasma concentration (C(max)) was similar in the groups (12.66, 17.25, 15.75, and 15.83 ng/mL, respectively), as was mean time to C(max) (6.2, 5.2, 4.3, and 5.4 h, respectively).",Effect of renal impairment on the pharmacokinetics of memantine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22863669/),h,5.2,181994,DB00915,Amantadine
,22863669,time to C(max),"Mean memantine maximum plasma concentration (C(max)) was similar in the groups (12.66, 17.25, 15.75, and 15.83 ng/mL, respectively), as was mean time to C(max) (6.2, 5.2, 4.3, and 5.4 h, respectively).",Effect of renal impairment on the pharmacokinetics of memantine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22863669/),h,4.3,181995,DB00915,Amantadine
,22863669,time to C(max),"Mean memantine maximum plasma concentration (C(max)) was similar in the groups (12.66, 17.25, 15.75, and 15.83 ng/mL, respectively), as was mean time to C(max) (6.2, 5.2, 4.3, and 5.4 h, respectively).",Effect of renal impairment on the pharmacokinetics of memantine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22863669/),h,5.4,181996,DB00915,Amantadine
,22863669,plasma elimination half-life,"Mean memantine plasma elimination half-life increased according to increasing renal impairment (61.15, 83.00, 100.13, and 124.31 h, respectively), while mean cumulative urinary recovery of unchanged memantine in 72 h after dosing decreased according to increasing renal impairment (33.68%, 33.47%, 23.60%, and 16.17%, respectively).",Effect of renal impairment on the pharmacokinetics of memantine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22863669/),h,61.15,181997,DB00915,Amantadine
,22863669,plasma elimination half-life,"Mean memantine plasma elimination half-life increased according to increasing renal impairment (61.15, 83.00, 100.13, and 124.31 h, respectively), while mean cumulative urinary recovery of unchanged memantine in 72 h after dosing decreased according to increasing renal impairment (33.68%, 33.47%, 23.60%, and 16.17%, respectively).",Effect of renal impairment on the pharmacokinetics of memantine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22863669/),h,83.00,181998,DB00915,Amantadine
,22863669,plasma elimination half-life,"Mean memantine plasma elimination half-life increased according to increasing renal impairment (61.15, 83.00, 100.13, and 124.31 h, respectively), while mean cumulative urinary recovery of unchanged memantine in 72 h after dosing decreased according to increasing renal impairment (33.68%, 33.47%, 23.60%, and 16.17%, respectively).",Effect of renal impairment on the pharmacokinetics of memantine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22863669/),h,100.13,181999,DB00915,Amantadine
,22863669,plasma elimination half-life,"Mean memantine plasma elimination half-life increased according to increasing renal impairment (61.15, 83.00, 100.13, and 124.31 h, respectively), while mean cumulative urinary recovery of unchanged memantine in 72 h after dosing decreased according to increasing renal impairment (33.68%, 33.47%, 23.60%, and 16.17%, respectively).",Effect of renal impairment on the pharmacokinetics of memantine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22863669/),h,124.31,182000,DB00915,Amantadine
,22863669,plasma elimination half-life,"Mean memantine plasma elimination half-life increased according to increasing renal impairment (61.15, 83.00, 100.13, and 124.31 h, respectively), while mean cumulative urinary recovery of unchanged memantine in 72 h after dosing decreased according to increasing renal impairment (33.68%, 33.47%, 23.60%, and 16.17%, respectively).",Effect of renal impairment on the pharmacokinetics of memantine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22863669/),%,33,182001,DB00915,Amantadine
,1740533,half-life,The half-life of amantadine after 42 days ingestion was 15.1 +/- 2.3 hours and was not different from 14.8 +/- 4.4 hours after an acute ingestion (mean +/- SD).,Effects of chronic amantadine hydrochloride ingestion on its and acetaminophen pharmacokinetics in young adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1740533/),h,15.1,198893,DB00915,Amantadine
,1740533,half-life,The half-life of amantadine after 42 days ingestion was 15.1 +/- 2.3 hours and was not different from 14.8 +/- 4.4 hours after an acute ingestion (mean +/- SD).,Effects of chronic amantadine hydrochloride ingestion on its and acetaminophen pharmacokinetics in young adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1740533/),h,14.8,198894,DB00915,Amantadine
,1740533,apparent volume of distribution,"However, chronic amantadine ingestion was associated with an increased apparent volume of distribution for acetaminophen, 1.1 +/- 0.1 L/kg compared with 0.9 +/- 0.1 L/kg, when the two drugs were concurrently ingested after a 2-week washout period.",Effects of chronic amantadine hydrochloride ingestion on its and acetaminophen pharmacokinetics in young adults. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1740533/),[l] / [kg],1.1,198895,DB00915,Amantadine
,1740533,apparent volume of distribution,"However, chronic amantadine ingestion was associated with an increased apparent volume of distribution for acetaminophen, 1.1 +/- 0.1 L/kg compared with 0.9 +/- 0.1 L/kg, when the two drugs were concurrently ingested after a 2-week washout period.",Effects of chronic amantadine hydrochloride ingestion on its and acetaminophen pharmacokinetics in young adults. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1740533/),[l] / [kg],0.9,198896,DB00915,Amantadine
,1740533,terminal,"This difference in kinetic distribution was not reflected in terminal acetaminophen half-life, 149 +/- 54 versus 151 +/- 55 minutes for chronic and acute amantadine ingestion, respectively.",Effects of chronic amantadine hydrochloride ingestion on its and acetaminophen pharmacokinetics in young adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1740533/),min,149,198897,DB00915,Amantadine
,1740533,half-life,"This difference in kinetic distribution was not reflected in terminal acetaminophen half-life, 149 +/- 54 versus 151 +/- 55 minutes for chronic and acute amantadine ingestion, respectively.",Effects of chronic amantadine hydrochloride ingestion on its and acetaminophen pharmacokinetics in young adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1740533/),min,149,198898,DB00915,Amantadine
,1740533,half-life,"This difference in kinetic distribution was not reflected in terminal acetaminophen half-life, 149 +/- 54 versus 151 +/- 55 minutes for chronic and acute amantadine ingestion, respectively.",Effects of chronic amantadine hydrochloride ingestion on its and acetaminophen pharmacokinetics in young adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1740533/),min,151,198899,DB00915,Amantadine
,1740533,Plasma acetaminophen clearance,Plasma acetaminophen clearance with chronic amantadine ingestion (5.8 +/- 2.6 mL/min/kg) was not different from that determined after acute coingestion of both drugs (4.3 +/- 1.1 mL/min/kg).,Effects of chronic amantadine hydrochloride ingestion on its and acetaminophen pharmacokinetics in young adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1740533/),[ml] / [kg·min],5.8,198900,DB00915,Amantadine
,1740533,Plasma acetaminophen clearance,Plasma acetaminophen clearance with chronic amantadine ingestion (5.8 +/- 2.6 mL/min/kg) was not different from that determined after acute coingestion of both drugs (4.3 +/- 1.1 mL/min/kg).,Effects of chronic amantadine hydrochloride ingestion on its and acetaminophen pharmacokinetics in young adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1740533/),[ml] / [kg·min],4.3,198901,DB00915,Amantadine
,26310825,bioavailability,"Memantine bioavailability was 41 and 63% for oral and patch administration, respectively.",Pharmacokinetics of Memantine after a Single and Multiple Dose of Oral and Patch Administration in Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26310825/),%,41,210365,DB00915,Amantadine
,26310825,bioavailability,"Memantine bioavailability was 41 and 63% for oral and patch administration, respectively.",Pharmacokinetics of Memantine after a Single and Multiple Dose of Oral and Patch Administration in Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26310825/),%,63,210366,DB00915,Amantadine
,30928488,bioavailability,"In the dog model, relative memantine bioavailability approaches 100% with sustained plasma levels of memantine over seven days and profiles that can be tuned by varying components of the formulation.",A pharmaceutical answer to nonadherence: Once weekly oral memantine for Alzheimer's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30928488/),%,100,215744,DB00915,Amantadine
,30176507,Flow rate,Flow rate was 0.4 mL/min and the total run time for each sample analysis was 2.0 min.,Validated HPLC-MS/MS method for quantification of ethylmethylhydroxypyridine succinate in rat brain and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30176507/),[ml] / [min],0.4,223262,DB00915,Amantadine
,30176507,total run time,Flow rate was 0.4 mL/min and the total run time for each sample analysis was 2.0 min.,Validated HPLC-MS/MS method for quantification of ethylmethylhydroxypyridine succinate in rat brain and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30176507/),min,2.0,223263,DB00915,Amantadine
,30176507,m/z,Ion transitions of m/z 138.0 → 123.0 for EMHP and m/z 152.0 → 135.0 for amantadine were selected in multiple reaction monitoring mode.,Validated HPLC-MS/MS method for quantification of ethylmethylhydroxypyridine succinate in rat brain and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30176507/),,138.0,223264,DB00915,Amantadine
,30176507,m/z,Ion transitions of m/z 138.0 → 123.0 for EMHP and m/z 152.0 → 135.0 for amantadine were selected in multiple reaction monitoring mode.,Validated HPLC-MS/MS method for quantification of ethylmethylhydroxypyridine succinate in rat brain and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30176507/),,123.0,223265,DB00915,Amantadine
,30176507,m/z,Ion transitions of m/z 138.0 → 123.0 for EMHP and m/z 152.0 → 135.0 for amantadine were selected in multiple reaction monitoring mode.,Validated HPLC-MS/MS method for quantification of ethylmethylhydroxypyridine succinate in rat brain and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30176507/),,152.0,223266,DB00915,Amantadine
,30176507,m/z,Ion transitions of m/z 138.0 → 123.0 for EMHP and m/z 152.0 → 135.0 for amantadine were selected in multiple reaction monitoring mode.,Validated HPLC-MS/MS method for quantification of ethylmethylhydroxypyridine succinate in rat brain and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30176507/),,135.0,223267,DB00915,Amantadine
,1770213,half-life,It was shown that the distribution phase after an i.v. administration is very short with a half-life of 2.1 min.,"Pharmacokinetic profile of the immunomodulating compound adamantylamide dipeptide (AdDP), a muramyl dipeptide derivative in mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1770213/),min,2.1,223495,DB00915,Amantadine
,1770213,half-life of elimination phase,"The half-life of elimination phase after the i.v. administration is about 2.85 hours, that is longer than those of MDP and its derivatives.","Pharmacokinetic profile of the immunomodulating compound adamantylamide dipeptide (AdDP), a muramyl dipeptide derivative in mice. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1770213/),h,2.85,223496,DB00915,Amantadine
,1770213,total body clearance,The total body clearance (30 ml/min/kg) is caused predominantly by metabolism of the compound.,"Pharmacokinetic profile of the immunomodulating compound adamantylamide dipeptide (AdDP), a muramyl dipeptide derivative in mice. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1770213/),[ml] / [kg·min],30,223497,DB00915,Amantadine
shorter,1770213,half-life,The concentration curve after a s.c. administration is characterized by a very fast absorption with a half-life shorter than 1 minute.,"Pharmacokinetic profile of the immunomodulating compound adamantylamide dipeptide (AdDP), a muramyl dipeptide derivative in mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1770213/),min,1,223498,DB00915,Amantadine
,1770213,distribution,"The distribution and elimination phases are prolonged (20 min, 11 hours respectively) in comparison with an i.v. injection.","Pharmacokinetic profile of the immunomodulating compound adamantylamide dipeptide (AdDP), a muramyl dipeptide derivative in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1770213/),min,20,223499,DB00915,Amantadine
,1770213,elimination phases,"The distribution and elimination phases are prolonged (20 min, 11 hours respectively) in comparison with an i.v. injection.","Pharmacokinetic profile of the immunomodulating compound adamantylamide dipeptide (AdDP), a muramyl dipeptide derivative in mice. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1770213/),h,11,223500,DB00915,Amantadine
,1770213,absolute bioavailability,The decreased absolute bioavailability after a s.c. administration (65%) is probably not biologically significant because of a slower release of the compound from the site of the s.c. administration.,"Pharmacokinetic profile of the immunomodulating compound adamantylamide dipeptide (AdDP), a muramyl dipeptide derivative in mice. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1770213/),%,65,223501,DB00915,Amantadine
,19338139,m/,"Following methanol-induced protein precipitation, the analytes were separated using a mobile phase comprised of methanol:water (0.5% formic acid) = 20:80 (v/v) on a commercially available column (150 mm x 2.1 mm I.D., 5 microm) and analyzed by electrospray ionization tandem mass spectrometry in the selected reaction monitoring (SRM) mode with the precursor to product ion transitions m/z 152.3-->110.2 for PAR, 152.3-->135.3 for ATH, 195.1-->138.3 for CAF, 275.2-->230.3 for CPM and 264.2-->58.2 for TMH.","Rapid simultaneous determination of paracetamol, amantadine hydrochloride, caffeine and chlorpheniramine maleate in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19338139/),,152.3,224505,DB00915,Amantadine
,19338139,m/,"Following methanol-induced protein precipitation, the analytes were separated using a mobile phase comprised of methanol:water (0.5% formic acid) = 20:80 (v/v) on a commercially available column (150 mm x 2.1 mm I.D., 5 microm) and analyzed by electrospray ionization tandem mass spectrometry in the selected reaction monitoring (SRM) mode with the precursor to product ion transitions m/z 152.3-->110.2 for PAR, 152.3-->135.3 for ATH, 195.1-->138.3 for CAF, 275.2-->230.3 for CPM and 264.2-->58.2 for TMH.","Rapid simultaneous determination of paracetamol, amantadine hydrochloride, caffeine and chlorpheniramine maleate in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19338139/),,152.3,224506,DB00915,Amantadine
,19338139,m/,"Following methanol-induced protein precipitation, the analytes were separated using a mobile phase comprised of methanol:water (0.5% formic acid) = 20:80 (v/v) on a commercially available column (150 mm x 2.1 mm I.D., 5 microm) and analyzed by electrospray ionization tandem mass spectrometry in the selected reaction monitoring (SRM) mode with the precursor to product ion transitions m/z 152.3-->110.2 for PAR, 152.3-->135.3 for ATH, 195.1-->138.3 for CAF, 275.2-->230.3 for CPM and 264.2-->58.2 for TMH.","Rapid simultaneous determination of paracetamol, amantadine hydrochloride, caffeine and chlorpheniramine maleate in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19338139/),,195.1,224507,DB00915,Amantadine
,19338139,m/,"Following methanol-induced protein precipitation, the analytes were separated using a mobile phase comprised of methanol:water (0.5% formic acid) = 20:80 (v/v) on a commercially available column (150 mm x 2.1 mm I.D., 5 microm) and analyzed by electrospray ionization tandem mass spectrometry in the selected reaction monitoring (SRM) mode with the precursor to product ion transitions m/z 152.3-->110.2 for PAR, 152.3-->135.3 for ATH, 195.1-->138.3 for CAF, 275.2-->230.3 for CPM and 264.2-->58.2 for TMH.","Rapid simultaneous determination of paracetamol, amantadine hydrochloride, caffeine and chlorpheniramine maleate in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19338139/),,138.3,224508,DB00915,Amantadine
,19338139,m/,"Following methanol-induced protein precipitation, the analytes were separated using a mobile phase comprised of methanol:water (0.5% formic acid) = 20:80 (v/v) on a commercially available column (150 mm x 2.1 mm I.D., 5 microm) and analyzed by electrospray ionization tandem mass spectrometry in the selected reaction monitoring (SRM) mode with the precursor to product ion transitions m/z 152.3-->110.2 for PAR, 152.3-->135.3 for ATH, 195.1-->138.3 for CAF, 275.2-->230.3 for CPM and 264.2-->58.2 for TMH.","Rapid simultaneous determination of paracetamol, amantadine hydrochloride, caffeine and chlorpheniramine maleate in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19338139/),,275.2,224509,DB00915,Amantadine
,19338139,m/,"Following methanol-induced protein precipitation, the analytes were separated using a mobile phase comprised of methanol:water (0.5% formic acid) = 20:80 (v/v) on a commercially available column (150 mm x 2.1 mm I.D., 5 microm) and analyzed by electrospray ionization tandem mass spectrometry in the selected reaction monitoring (SRM) mode with the precursor to product ion transitions m/z 152.3-->110.2 for PAR, 152.3-->135.3 for ATH, 195.1-->138.3 for CAF, 275.2-->230.3 for CPM and 264.2-->58.2 for TMH.","Rapid simultaneous determination of paracetamol, amantadine hydrochloride, caffeine and chlorpheniramine maleate in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19338139/),,230.3,224510,DB00915,Amantadine
,19338139,m/,"Following methanol-induced protein precipitation, the analytes were separated using a mobile phase comprised of methanol:water (0.5% formic acid) = 20:80 (v/v) on a commercially available column (150 mm x 2.1 mm I.D., 5 microm) and analyzed by electrospray ionization tandem mass spectrometry in the selected reaction monitoring (SRM) mode with the precursor to product ion transitions m/z 152.3-->110.2 for PAR, 152.3-->135.3 for ATH, 195.1-->138.3 for CAF, 275.2-->230.3 for CPM and 264.2-->58.2 for TMH.","Rapid simultaneous determination of paracetamol, amantadine hydrochloride, caffeine and chlorpheniramine maleate in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19338139/),,264.2,224511,DB00915,Amantadine
,34218083,IC50,"Among them, compound B401 significantly improved the inhibition potency with human and murine sEH IC50 values as 0.4 nM and 0.5 nM, respectively.",Discovery of memantyl urea derivatives as potent soluble epoxide hydrolase inhibitors against lipopolysaccharide-induced sepsis. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34218083/),nM,0.4,226951,DB00915,Amantadine
,34218083,IC50,"Among them, compound B401 significantly improved the inhibition potency with human and murine sEH IC50 values as 0.4 nM and 0.5 nM, respectively.",Discovery of memantyl urea derivatives as potent soluble epoxide hydrolase inhibitors against lipopolysaccharide-induced sepsis. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34218083/),nM,0.5,226952,DB00915,Amantadine
,1436383,ED50,"Memantine increased the threshold for electroconvulsions, when administered at 1.0-6.0 mg/kg (i.p.) and given in subthreshold doses of 0.0156, 0.0625, 0.125 and 0.5 mg/kg (i.p.) potentiated the protective efficacy of valproate, against maximal electroshock (50 mA)-induced seizures in mice, lowering the ED50 from 235 to 197, 172, 164 and 130 mg/kg, respectively.",Antiparkinsonian drugs memantine and trihexyphenidyl potentiate the anticonvulsant activity of valproate against maximal electroshock-induced seizures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1436383/),[mg] / [kg],235,230125,DB00915,Amantadine
,1436383,ED50,"Memantine increased the threshold for electroconvulsions, when administered at 1.0-6.0 mg/kg (i.p.) and given in subthreshold doses of 0.0156, 0.0625, 0.125 and 0.5 mg/kg (i.p.) potentiated the protective efficacy of valproate, against maximal electroshock (50 mA)-induced seizures in mice, lowering the ED50 from 235 to 197, 172, 164 and 130 mg/kg, respectively.",Antiparkinsonian drugs memantine and trihexyphenidyl potentiate the anticonvulsant activity of valproate against maximal electroshock-induced seizures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1436383/),[mg] / [kg],197,230126,DB00915,Amantadine
,1436383,ED50,"Memantine increased the threshold for electroconvulsions, when administered at 1.0-6.0 mg/kg (i.p.) and given in subthreshold doses of 0.0156, 0.0625, 0.125 and 0.5 mg/kg (i.p.) potentiated the protective efficacy of valproate, against maximal electroshock (50 mA)-induced seizures in mice, lowering the ED50 from 235 to 197, 172, 164 and 130 mg/kg, respectively.",Antiparkinsonian drugs memantine and trihexyphenidyl potentiate the anticonvulsant activity of valproate against maximal electroshock-induced seizures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1436383/),[mg] / [kg],172,230127,DB00915,Amantadine
,1436383,ED50,"Memantine increased the threshold for electroconvulsions, when administered at 1.0-6.0 mg/kg (i.p.) and given in subthreshold doses of 0.0156, 0.0625, 0.125 and 0.5 mg/kg (i.p.) potentiated the protective efficacy of valproate, against maximal electroshock (50 mA)-induced seizures in mice, lowering the ED50 from 235 to 197, 172, 164 and 130 mg/kg, respectively.",Antiparkinsonian drugs memantine and trihexyphenidyl potentiate the anticonvulsant activity of valproate against maximal electroshock-induced seizures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1436383/),[mg] / [kg],164,230128,DB00915,Amantadine
,1436383,ED50,"Memantine increased the threshold for electroconvulsions, when administered at 1.0-6.0 mg/kg (i.p.) and given in subthreshold doses of 0.0156, 0.0625, 0.125 and 0.5 mg/kg (i.p.) potentiated the protective efficacy of valproate, against maximal electroshock (50 mA)-induced seizures in mice, lowering the ED50 from 235 to 197, 172, 164 and 130 mg/kg, respectively.",Antiparkinsonian drugs memantine and trihexyphenidyl potentiate the anticonvulsant activity of valproate against maximal electroshock-induced seizures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1436383/),[mg] / [kg],130,230129,DB00915,Amantadine
,1436383,ED50,"Trihexyphenidyl, applied in doses of 30 and 50 mg/kg (i.p.), did not influence the electroconvulsive threshold per se but when combined with valproate, strongly enhanced its anticonvulsant activity against maximal electroshock-induced seizures lowering the ED50 from 206 to 103 and 46 mg/kg, respectively.",Antiparkinsonian drugs memantine and trihexyphenidyl potentiate the anticonvulsant activity of valproate against maximal electroshock-induced seizures. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1436383/),[mg] / [kg],206,230130,DB00915,Amantadine
,1436383,ED50,"Trihexyphenidyl, applied in doses of 30 and 50 mg/kg (i.p.), did not influence the electroconvulsive threshold per se but when combined with valproate, strongly enhanced its anticonvulsant activity against maximal electroshock-induced seizures lowering the ED50 from 206 to 103 and 46 mg/kg, respectively.",Antiparkinsonian drugs memantine and trihexyphenidyl potentiate the anticonvulsant activity of valproate against maximal electroshock-induced seizures. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1436383/),[mg] / [kg],103,230131,DB00915,Amantadine
,1436383,ED50,"Trihexyphenidyl, applied in doses of 30 and 50 mg/kg (i.p.), did not influence the electroconvulsive threshold per se but when combined with valproate, strongly enhanced its anticonvulsant activity against maximal electroshock-induced seizures lowering the ED50 from 206 to 103 and 46 mg/kg, respectively.",Antiparkinsonian drugs memantine and trihexyphenidyl potentiate the anticonvulsant activity of valproate against maximal electroshock-induced seizures. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1436383/),[mg] / [kg],46,230132,DB00915,Amantadine
,7212501,half-life of elimination,"The half-life of elimination in subjects with normal renal function was 11.8 +/- 2.1 hours (range, 9.7 to 14.5 h).",Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7212501/),h,11.8,233260,DB00915,Amantadine
,7212501,half-lives of elimination,Eight patients with various degrees of renal insufficiency (creatinine clearance from 43.1 to 5.9 mL/min . 1.73 m2) had half-lives of elimination from 18.5 h to 33.8 days.,Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7212501/),h,18.5,233261,DB00915,Amantadine
,7212501,half-lives of elimination,Eight patients with various degrees of renal insufficiency (creatinine clearance from 43.1 to 5.9 mL/min . 1.73 m2) had half-lives of elimination from 18.5 h to 33.8 days.,Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7212501/),d,33.8,233262,DB00915,Amantadine
,7212501,half-life of elimination,"The mean half-life of elimination during chronic hemodialysis was 8.3 days (range, 7.0 to 10.3).",Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7212501/),d,8.3,233263,DB00915,Amantadine
,6847173,plasma drug concentrations,"Mean plasma drug concentrations at 4 h after the first dose were lower in rimantadine recipients given 100- (140 versus 300 ng/ml for rimantadine and amantadine, respectively; P less than 10(-5)) or 200-mg doses (310 versus 633 ng/ml; P less than 10(-5)).",Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6847173/),[ng] / [ml],140,235925,DB00915,Amantadine
,6847173,plasma drug concentrations,"Mean plasma drug concentrations at 4 h after the first dose were lower in rimantadine recipients given 100- (140 versus 300 ng/ml for rimantadine and amantadine, respectively; P less than 10(-5)) or 200-mg doses (310 versus 633 ng/ml; P less than 10(-5)).",Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6847173/),[ng] / [ml],300,235926,DB00915,Amantadine
,6847173,plasma drug concentrations,"Mean plasma drug concentrations at 4 h after the first dose were lower in rimantadine recipients given 100- (140 versus 300 ng/ml for rimantadine and amantadine, respectively; P less than 10(-5)) or 200-mg doses (310 versus 633 ng/ml; P less than 10(-5)).",Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6847173/),[ng] / [ml],310,235927,DB00915,Amantadine
,6847173,plasma drug concentrations,"Mean plasma drug concentrations at 4 h after the first dose were lower in rimantadine recipients given 100- (140 versus 300 ng/ml for rimantadine and amantadine, respectively; P less than 10(-5)) or 200-mg doses (310 versus 633 ng/ml; P less than 10(-5)).",Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6847173/),[ng] / [ml],633,235928,DB00915,Amantadine
,498714,Plasma half-lifes (t1/2s),Plasma half-lifes (t1/2s) ranged from 10.2 to 31.4 hr and were independent of dose or creatinine clearance.,Amantadine kinetics in healthy young subjects after long-term dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/498714/),h,10.2 to 31.4,238527,DB00915,Amantadine
,26280281,flow rate,"The analytes were separated on C18 reversed phase column with mobile phase consisting of a mixture of methanol and 10mM ammonium acetate, pH 5 (92:8 v/v) at a flow rate of 0.7mL/min.",Development of an LC-MS/MS method for simultaneous determination of memantine and donepezil in rat plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26280281/),[ml] / [min],0.7,240406,DB00915,Amantadine
greater,26280281,recovery,The mean recovery of MM and DPZ was found to be greater than 80%.,Development of an LC-MS/MS method for simultaneous determination of memantine and donepezil in rat plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26280281/),%,80,240407,DB00915,Amantadine
,17038888,elimination constant,"The elimination constant in brain tissue was determined to be 0.00447 [1/h], resulting in a t1/2 of 6.5 days for the mean patient in the population investigated (n = 19).",Pharmacokinetic characterization of amantadine in human brain tissue. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038888/),[1] / [h],0.00447,254591,DB00915,Amantadine
,17038888,t1/2,"The elimination constant in brain tissue was determined to be 0.00447 [1/h], resulting in a t1/2 of 6.5 days for the mean patient in the population investigated (n = 19).",Pharmacokinetic characterization of amantadine in human brain tissue. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038888/),d,6.5,254592,DB00915,Amantadine
,17038888,apparent volume of distribution,An estimate of 65.5 L was obtained for the apparent volume of distribution.,Pharmacokinetic characterization of amantadine in human brain tissue. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038888/),l,65.5,254593,DB00915,Amantadine
,18498913,recoveries,"The mean recoveries of the 0.4, 20.0, and 180.0 ng/mL levels were 78.87%, 81.55%, and 81.98%, respectively.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),%,78.87,254806,DB00915,Amantadine
,18498913,recoveries,"The mean recoveries of the 0.4, 20.0, and 180.0 ng/mL levels were 78.87%, 81.55%, and 81.98%, respectively.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),%,81.55,254807,DB00915,Amantadine
,18498913,recoveries,"The mean recoveries of the 0.4, 20.0, and 180.0 ng/mL levels were 78.87%, 81.55%, and 81.98%, respectively.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),%,81.98,254808,DB00915,Amantadine
,18498913,C(max),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[ng] / [ml],6.20,254809,DB00915,Amantadine
,18498913,C(max),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[ng] / [ml],11.60,254810,DB00915,Amantadine
,18498913,C(max),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[ng] / [ml],25.34,254811,DB00915,Amantadine
,18498913,T(max),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),h,5.70,254812,DB00915,Amantadine
,18498913,T(max),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),h,6.00,254813,DB00915,Amantadine
,18498913,T(max),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),h,6.89,254814,DB00915,Amantadine
,18498913,AUC(0-t),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[h·ng] / [ml],486.19,254815,DB00915,Amantadine
,18498913,AUC(0-t),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[h·ng] / [ml],889.32,254816,DB00915,Amantadine
,18498913,AUC(0-t),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[h·ng] / [ml],1772.91,254817,DB00915,Amantadine
,18498913,AUC(0-infinity),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[h·ng] / [ml],540.05,254818,DB00915,Amantadine
,18498913,AUC(0-infinity),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[h·ng] / [ml],932.07,254819,DB00915,Amantadine
,18498913,AUC(0-infinity),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[h·ng] / [ml],1853.29,254820,DB00915,Amantadine
,18498913,t(1/2),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),h,66.86,254821,DB00915,Amantadine
,18498913,t(1/2),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),h,63.57,254822,DB00915,Amantadine
,18498913,t(1/2),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),h,62.06,254823,DB00915,Amantadine
,18498913,MRT,"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),,99.37,254824,DB00915,Amantadine
,18498913,MRT,"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),,91.73,254825,DB00915,Amantadine
,18498913,T(max),"The main pharmacokinetic parameters found for memantine at doses of 5 mg once daily for 14 days were as follows: T(max), 6.80 (2.46) h; C(ssmax), 19.69 (2.00) ng/mL; C(ssmin), 12.76 (2.80) ng/mL; C(ssav), 16.10 (2.46) ng/mL; t(1/2), 64.57 (15.78) h; MRT, 93.17 (23.38) h; AUC(ss),386.37 (59.00) ng x h/mL; and DF, 44.47% (15.27%).",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),h,6.80,254826,DB00915,Amantadine
,18498913,C(ssmax),"The main pharmacokinetic parameters found for memantine at doses of 5 mg once daily for 14 days were as follows: T(max), 6.80 (2.46) h; C(ssmax), 19.69 (2.00) ng/mL; C(ssmin), 12.76 (2.80) ng/mL; C(ssav), 16.10 (2.46) ng/mL; t(1/2), 64.57 (15.78) h; MRT, 93.17 (23.38) h; AUC(ss),386.37 (59.00) ng x h/mL; and DF, 44.47% (15.27%).",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[ng] / [ml],19.69,254827,DB00915,Amantadine
,18498913,C(ssmin),"The main pharmacokinetic parameters found for memantine at doses of 5 mg once daily for 14 days were as follows: T(max), 6.80 (2.46) h; C(ssmax), 19.69 (2.00) ng/mL; C(ssmin), 12.76 (2.80) ng/mL; C(ssav), 16.10 (2.46) ng/mL; t(1/2), 64.57 (15.78) h; MRT, 93.17 (23.38) h; AUC(ss),386.37 (59.00) ng x h/mL; and DF, 44.47% (15.27%).",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[ng] / [ml],12.76,254828,DB00915,Amantadine
,18498913,C(ssav),"The main pharmacokinetic parameters found for memantine at doses of 5 mg once daily for 14 days were as follows: T(max), 6.80 (2.46) h; C(ssmax), 19.69 (2.00) ng/mL; C(ssmin), 12.76 (2.80) ng/mL; C(ssav), 16.10 (2.46) ng/mL; t(1/2), 64.57 (15.78) h; MRT, 93.17 (23.38) h; AUC(ss),386.37 (59.00) ng x h/mL; and DF, 44.47% (15.27%).",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[ng] / [ml],16.10,254829,DB00915,Amantadine
,18498913,t(1/2),"The main pharmacokinetic parameters found for memantine at doses of 5 mg once daily for 14 days were as follows: T(max), 6.80 (2.46) h; C(ssmax), 19.69 (2.00) ng/mL; C(ssmin), 12.76 (2.80) ng/mL; C(ssav), 16.10 (2.46) ng/mL; t(1/2), 64.57 (15.78) h; MRT, 93.17 (23.38) h; AUC(ss),386.37 (59.00) ng x h/mL; and DF, 44.47% (15.27%).",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),h,64.57,254830,DB00915,Amantadine
,18498913,MRT,"The main pharmacokinetic parameters found for memantine at doses of 5 mg once daily for 14 days were as follows: T(max), 6.80 (2.46) h; C(ssmax), 19.69 (2.00) ng/mL; C(ssmin), 12.76 (2.80) ng/mL; C(ssav), 16.10 (2.46) ng/mL; t(1/2), 64.57 (15.78) h; MRT, 93.17 (23.38) h; AUC(ss),386.37 (59.00) ng x h/mL; and DF, 44.47% (15.27%).",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),h,93.17,254831,DB00915,Amantadine
,18498913,AUC(ss),"The main pharmacokinetic parameters found for memantine at doses of 5 mg once daily for 14 days were as follows: T(max), 6.80 (2.46) h; C(ssmax), 19.69 (2.00) ng/mL; C(ssmin), 12.76 (2.80) ng/mL; C(ssav), 16.10 (2.46) ng/mL; t(1/2), 64.57 (15.78) h; MRT, 93.17 (23.38) h; AUC(ss),386.37 (59.00) ng x h/mL; and DF, 44.47% (15.27%).",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[h·ng] / [ml],386.37,254832,DB00915,Amantadine
,18498913,DF,"The main pharmacokinetic parameters found for memantine at doses of 5 mg once daily for 14 days were as follows: T(max), 6.80 (2.46) h; C(ssmax), 19.69 (2.00) ng/mL; C(ssmin), 12.76 (2.80) ng/mL; C(ssav), 16.10 (2.46) ng/mL; t(1/2), 64.57 (15.78) h; MRT, 93.17 (23.38) h; AUC(ss),386.37 (59.00) ng x h/mL; and DF, 44.47% (15.27%).",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),%,44.47,254833,DB00915,Amantadine
,15632953,T(max),"LA-12 was rapidly absorbed, as indicated by a T(max) of total Pt within 0.5-1.5 h after administration.",Single-dose pharmacokinetics of a novel oral platinum cytostatic drug ([OC-6-43]-bis[acetato][1-adamantylamine]amminedichloroplatinum [IV]) in pigs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15632953/),h,0.5-1.5,258793,DB00915,Amantadine
,15632953,maximum plasma concentration,The mean (SEM) values for maximum plasma concentration (0.060 +/- 0.025 and 0.39 +/- 0.08 mg/l) and the area under the plasma concentration vs. time curve (12.6 +/- 5.6 and 36.3 +/- 2.0 mg.h/l) increased less than proportionally to the increase in the dose.,Single-dose pharmacokinetics of a novel oral platinum cytostatic drug ([OC-6-43]-bis[acetato][1-adamantylamine]amminedichloroplatinum [IV]) in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15632953/),[mg] / [l],0.060,258794,DB00915,Amantadine
,15632953,maximum plasma concentration,The mean (SEM) values for maximum plasma concentration (0.060 +/- 0.025 and 0.39 +/- 0.08 mg/l) and the area under the plasma concentration vs. time curve (12.6 +/- 5.6 and 36.3 +/- 2.0 mg.h/l) increased less than proportionally to the increase in the dose.,Single-dose pharmacokinetics of a novel oral platinum cytostatic drug ([OC-6-43]-bis[acetato][1-adamantylamine]amminedichloroplatinum [IV]) in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15632953/),[mg] / [l],0.39,258795,DB00915,Amantadine
,15632953,area under the plasma concentration vs. time curve,The mean (SEM) values for maximum plasma concentration (0.060 +/- 0.025 and 0.39 +/- 0.08 mg/l) and the area under the plasma concentration vs. time curve (12.6 +/- 5.6 and 36.3 +/- 2.0 mg.h/l) increased less than proportionally to the increase in the dose.,Single-dose pharmacokinetics of a novel oral platinum cytostatic drug ([OC-6-43]-bis[acetato][1-adamantylamine]amminedichloroplatinum [IV]) in pigs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15632953/),[h·mg] / [l],12.6,258796,DB00915,Amantadine
,15632953,area under the plasma concentration vs. time curve,The mean (SEM) values for maximum plasma concentration (0.060 +/- 0.025 and 0.39 +/- 0.08 mg/l) and the area under the plasma concentration vs. time curve (12.6 +/- 5.6 and 36.3 +/- 2.0 mg.h/l) increased less than proportionally to the increase in the dose.,Single-dose pharmacokinetics of a novel oral platinum cytostatic drug ([OC-6-43]-bis[acetato][1-adamantylamine]amminedichloroplatinum [IV]) in pigs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15632953/),[h·mg] / [l],36.3,258797,DB00915,Amantadine
,15632953,urinary excretion,"The mean (SEM) Pt urinary excretion determined over a 6-h postdose period achieved only 1.9% and 0.8% of the administered doses, respectively.",Single-dose pharmacokinetics of a novel oral platinum cytostatic drug ([OC-6-43]-bis[acetato][1-adamantylamine]amminedichloroplatinum [IV]) in pigs. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15632953/),%,1.9,258798,DB00915,Amantadine
,15632953,urinary excretion,"The mean (SEM) Pt urinary excretion determined over a 6-h postdose period achieved only 1.9% and 0.8% of the administered doses, respectively.",Single-dose pharmacokinetics of a novel oral platinum cytostatic drug ([OC-6-43]-bis[acetato][1-adamantylamine]amminedichloroplatinum [IV]) in pigs. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15632953/),%,0.8,258799,DB00915,Amantadine
,15632953,recoveries,"Platinum recoveries in feces over 10 days after dosing reached 0.4% and 2.6% of the administered dose, respectively.",Single-dose pharmacokinetics of a novel oral platinum cytostatic drug ([OC-6-43]-bis[acetato][1-adamantylamine]amminedichloroplatinum [IV]) in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15632953/),%,0.4,258800,DB00915,Amantadine
,15632953,recoveries,"Platinum recoveries in feces over 10 days after dosing reached 0.4% and 2.6% of the administered dose, respectively.",Single-dose pharmacokinetics of a novel oral platinum cytostatic drug ([OC-6-43]-bis[acetato][1-adamantylamine]amminedichloroplatinum [IV]) in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15632953/),%,2.6,258801,DB00915,Amantadine
,15803448,retention times,"The retention times of AMA and RIM derivatives were 12.6 and 22.2 min and the lower limits of detection were 0.025 and 0.016 microg/mL, respectively.",Simultaneous determination of amantadine and rimantadine by HPLC in rat plasma with pre-column derivatization and fluorescence detection for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15803448/),min,12.6,264017,DB00915,Amantadine
,15803448,retention times,"The retention times of AMA and RIM derivatives were 12.6 and 22.2 min and the lower limits of detection were 0.025 and 0.016 microg/mL, respectively.",Simultaneous determination of amantadine and rimantadine by HPLC in rat plasma with pre-column derivatization and fluorescence detection for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15803448/),min,22.2,264018,DB00915,Amantadine
,15803448,Bioavailability,"Bioavailability of AMA and RIM was 34.9 and 37.2%, respectively.",Simultaneous determination of amantadine and rimantadine by HPLC in rat plasma with pre-column derivatization and fluorescence detection for pharmacokinetic studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15803448/),%,34.9,264019,DB00915,Amantadine
,15803448,Bioavailability,"Bioavailability of AMA and RIM was 34.9 and 37.2%, respectively.",Simultaneous determination of amantadine and rimantadine by HPLC in rat plasma with pre-column derivatization and fluorescence detection for pharmacokinetic studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15803448/),%,37.2,264020,DB00915,Amantadine
